RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the first quarter ended March 31, 2009. Total product revenue was $44.8 million for the first quarter of 2009, compared to $34.3 million for the first quarter of 2008. XIFAXAN® revenue for the first quarter of 2009 was $24.1 million, a 44% increase compared to the first quarter of 2008. MOVIPREP®, OSMOPREP® and VISICOL®, which comprise our bowel cleansing product line, generated revenue of $12.7 million for the first quarter of 2009, compared to $10.3 million for the first quarter of 2008.
